Loteprednol etabonate

Cat. No.: OB0225WX-2432

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Loteprednol etabonate is a potent agonist of the glucocorticoid receptor, utilized at the molecular level to manage inflammatory signaling.

Synonym: 82034-46-6; Lotemax; Alrex; HGP-1; Inveltys; P-5604; Chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate; Loteprednol etabonate Opphthalmic suspension; P 5604; Chloromethyl 11beta,17-dihydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate, 17-(ethyl carbonate); Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; Loterox; Locort; Androsta-1,4-diene-17-carboxylic acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11beta,17alpha)-; Etabonate, Loteprednol; Airex; Lotemax SM; Chloromethyl 17alpha-((ethoxycarbonyl)oxy)-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate; Androsta-1,4-diene-17-carboxylic Acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl Ester,(11beta,17alpha)-; chloromethyl (1R,3aS,3bS,9aR,9bS,10S,11aS)-1-[(ethoxycarbonyl)oxy]-10-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1-carboxylate; chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-14-carboxylate; Chlorometyl 17alpha-((ethoxycarbonyl)oxy)-11beta-hydroxy-3-oxoandrosla-1,4-diene-17beta-carboxylate

CAS No.: 82034-46-6

Compound CID: 444025

Formula: C₂₄H₃₁ClO₇

Formula Weight: 466.95

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Loteprednol etabonate is applied in ophthalmology research as a site-active corticosteroid to study the reduction of ocular inflammatory responses with a minimized impact on intraocular pressure.